Rinvoq

News

AbbVie lifted by lengthy delay to generics of Rinvoq

Shares in AbbVie were lifted today after the company revealed that it has settled patent litigation with generic drugmakers on blockbuster Rinvoq.

News

Rinvoq cleared for giant cell arteritis in EU, ahead of US

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis.

News

AbbVie closes on Rinvoq approval in inflamed artery disease

AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.

News

AbbVie’s new drugs keep post-Humira prospects on track

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th

News

AbbVie’s growth drugs fail to offset Humira competition

Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it

News